Mylan has received a long-awaited approval for the first US generic rival to GlaxoSmithKline’s (GSK’s) Advair Diskus (fluticasone/salmeterol) asthma treatment, putting the firm around a year ahead of other US generics being pursued by competitors Sandoz and Hikma.
Mylan’s Nod For US Advair Rival Puts It A Year Ahead Of The Pack
The FDA’s approval for Mylan’s Wixela Inhub generic rival to GSK’s Advair Diskus is likely to give the company around a year’s head-start on other US generics being developed by Sandoz and Hikma.
